

[AUTHOR: This is the subedited preproof of your paper, not including figures. Please correct it in line with the instructions and comments below.

- Check the title and the first paragraph with care, as they may have been re-written to aid accessibility for non-specialist readers. As part of our commitment to quality, the title and first paragraph will be read by another subeditor before the text is finalized, and further changes may be made.
- Check the numbering for affiliations with care.
- Check all author names and Acknowledgements carefully to ensure that they are correct.
- Check the email address of the corresponding author and the Competing Interests statement.
- Check that there has been no corruption of mathematical symbols, noting that for ‘approximately equal to’ we use ‘ $\approx$ ’ in equations and ‘ $\sim$ ’ elsewhere. We number only those equations that are referred to by number in the text.
- Ensure that the sex and other characteristics of organisms studied (age, species, strain) that may influence results are described.
- Ensure that accession numbers for any new sequences determined in this paper have been supplied.
- Ensure that, where practicable, all figures, tables and other discrete elements of Supplementary Information are referred to at least once in the paper at an appropriate place in the text or figure legends.
- Update any ‘in the press’, ‘submitted’ or ‘preprint’ references if possible, and note any queries embedded in the reference list.
- Single-letter variables are set in italics (but not their subscripts unless these are also variables). We do not use italics for emphasis. Genetic material is set in italics, but gene products are set upright. Please check that italicization is correct throughout.
- We reserve ‘significant’ and its derivatives to mean statistically significant. Please reword any instance of ‘significant’, ‘significance’, etc. where this is not the intended meaning.

[AUTHOR: A proof will be produced on the basis of your corrections to this preproof. For this later stage of production we use an online ‘eproof’ tool, where you can make corrections directly to the text within the tool and also mark up corrections to the copyedited figures. You will receive a link to the eproof tool via email later in the production process.

When you receive the eproof link, please check that the display items are as follows (ms no:): Figs none (black & white); 1–4(colour); Tables: None; Boxes: None; Extended Data display items: Figs 1–10; SI: yes. The eproof contains the main-text figures edited by us and (if present) the Extended Data items (unedited except for the legends) and the Supplementary Information (unedited).

Please note that the eproof should be amended in only one browser window at any one time, otherwise changes will be overwritten.

Please check the edits to all main-text figures (and tables, if any) very carefully, and ensure that any error bars in the figures are defined in the figure legends. Extended Data items may be revised only if there are errors in the original submissions. If you need to revise any Extended Data items please upload these files when you submit your corrections to this preproof.

- A single sentence summarizing your paper (websum), which will appear online on the table of contents and in e-alerts, has been provided below. Please check this sentence for accuracy and appropriate emphasis.]

[TYPESETTER: websum: Comparison of transcriptomic data from immune-stimulated cells across different species sheds light on the architecture of the innate immune response.]

## Gene expression variability across cells and species shapes innate immunity

Tzachi Hagai<sup>1,2\*</sup>, Xi Chen<sup>1</sup>, Ricardo J. Miragaia<sup>1,3</sup>, Raghd Rostom<sup>1,2</sup>, Tomás Gomes<sup>1</sup>, Natalia Kunowska<sup>1</sup>, Johan Henriksson<sup>1</sup>, Jong-Eun Park<sup>1</sup>, Valentina Proserpio<sup>4,5</sup>, Giacomo Donati<sup>4,6</sup>, Lara Bossini-Castillo<sup>1</sup>, Felipe A. Vieira Braga<sup>1,7</sup>, Guy Naamati<sup>2</sup>, James Fletcher<sup>8</sup>, Emily Stephenson<sup>8</sup>, Peter Vegh<sup>8</sup>, Gosia Trynka<sup>1</sup>, Ivanela

Kondova<sup>9</sup>, Mike Dennis<sup>10</sup>, Muzlifah Haniffa<sup>8,11</sup>, Armita Nourmohammad<sup>12,13</sup>, Michael Lässig<sup>14</sup> & Sarah A. Teichmann<sup>1,2,15\*</sup>

<sup>1</sup>Wellcome Sanger Institute, Cambridge, UK.

<sup>2</sup>EMBL- European Bioinformatics Institute, Cambridge, UK.

<sup>3</sup>Centre of Biological Engineering, University of Minho, Braga, Portugal.

<sup>4</sup>Department of Life Sciences and Systems Biology, University of Turin, Torino, Italy.

<sup>5</sup>Italian Institute for Genomic Medicine (IIGM), Torino, Italy.

<sup>6</sup>Molecular Biotechnology Center, University of Turin, Torino, Italy.

<sup>7</sup>Open Targets, Wellcome Sanger Institute, Cambridge, UK.

<sup>8</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

<sup>9</sup>Division of Pathology and Microbiology, Animal Science Department, Biomedical Primate Research Centre, Rijswijk, the Netherlands.

<sup>10</sup>Research Department, Public Health England, National Infection Service, Porton Down, UK.

<sup>11</sup>Department of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

<sup>12</sup>Max Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.

<sup>13</sup>Department of Physics, University of Washington, Seattle, WA, USA.

<sup>14</sup>Institute for Biological Physics, University of Cologne, Cologne, Germany.

<sup>15</sup>Theory of Condensed Matter Group, Cavendish Laboratory, University of Cambridge, Cambridge, UK.

\*email: tzachi@ebi.ac.uk; st9@sanger.ac.uk

**As the first line of defence against pathogens, cells mount an innate immune response, which varies widely from cell to cell. The response must be potent but carefully controlled to avoid self-damage. How these constraints have shaped the evolution of innate immunity remains poorly understood. Here we characterize the innate immune response's transcriptional divergence between species and variability in expression among cells. Using bulk and single-cell transcriptomics in fibroblasts and mononuclear phagocytes from different species, challenged with immune stimuli, we identify the architecture of the innate immune response. Transcriptionally diverging genes, including cytokines and chemokines, vary across cells and have distinct promoter structures. Conversely, genes that are involved in regulation of this response, such as transcription factors and kinases, are conserved between species and display low cell-to-cell variability in expression. We suggest that this expression pattern, which is observed**

**across species and conditions, has evolved as a mechanism for fine-tuned regulation to achieve an effective but balanced response.**

The innate immune response is a cell-intrinsic defence program that is rapidly upregulated upon infection in most cell types. It acts to inhibit pathogen replication while signalling the pathogen's presence to other cells. This programme involves the modulation of several cellular pathways, including production of antiviral and inflammatory cytokines, upregulation of genes that restrict pathogens, and induction of cell death<sup>1,2</sup>.

An important characteristic of the innate immune response is the rapid evolution that many of its genes have undergone along the vertebrate lineage<sup>3,4</sup>. This rapid evolution is often attributed to pathogen-driven selection<sup>5–7</sup>.

Another hallmark of this response is its high level of heterogeneity among responding cells: there is extensive cell-to-cell variability in response to pathogen infection<sup>8,9</sup> or to pathogen-associated molecular patterns (PAMPs)<sup>10,11</sup>. The functional importance of this variability is unclear.

These two characteristics—rapid divergence in the course of evolution and high cell-to-cell variability—seem to be at odds with the strong regulatory constraint imposed on the host immune response: the need to execute a well-coordinated and carefully balanced programme to avoid tissue damage and pathological immune conditions<sup>12–15</sup>. How this tight regulation is maintained despite rapid evolutionary divergence and high cell-to-cell variability remains unclear, but it is central to our understanding of the innate immune response and its evolution.

Here, we study the evolution of this programme using two cell types—fibroblasts and mononuclear phagocytes—in different mammalian clades challenged with several immune stimuli (Fig. 1a).

Our main experimental system uses primary dermal fibroblasts, which are commonly used in immunological studies<sup>8,13</sup>. We compare the response of fibroblasts from primates (human and macaque) and rodents (mouse and rat) to poly I:C, a synthetic double-stranded RNA (dsRNA; Fig. 1a, left). Poly I:C is frequently used to mimic viral infection as it rapidly elicits an antiviral response<sup>16</sup>.

We comprehensively characterize the transcriptional changes between species and among individual cells in their innate immune response. We use population (bulk) transcriptomics to investigate transcriptional divergence between species, and single-cell

transcriptomics to estimate cell-to-cell variability in gene expression. Using promoter sequence analyses along with ChIP-seq, we study how changes in the expression of each gene between species and across cells relate to the architecture of its promoter. Furthermore, we examine the relationship between cross-species divergence in gene sequence and expression and constraints imposed by host-pathogen interactions.

Additionally, we use a second system—bone marrow-derived mononuclear phagocytes from mouse, rat, rabbit and pig challenged with lipopolysaccharide (LPS), a commonly used PAMP of bacterial origin (Fig. 1a, right).

Taken together, these two systems provide insights into the architecture of the immune response across species, cell types and immune challenges.

### **Transcriptional divergence in immune response**

First, we studied the transcriptional response of fibroblasts to stimulation with dsRNA (poly I:C) across the four species (human, macaque, rat and mouse). We generated bulk RNA-sequencing (RNA-seq) data for each species after 4 h of stimulation, along with respective controls (see Fig. 1a and Methods).

In all species, dsRNA treatment induced rapid upregulation of genes encoding expected antiviral and inflammatory products, including IFNB, TNF, IL1A and CCL5 (see also Supplementary Table 3). Focusing on one-to-one orthologues, we performed correlation analysis between species and observed a similar transcriptional response (Spearman correlation,  $P < 10^{-10}$  in all comparisons; Extended Data Fig. 1), as reported in other immune contexts<sup>17–19</sup>. Furthermore, the response tended to be more strongly correlated between closely related species than between more distantly related species, as in other expression programmes<sup>20–24</sup>.

We characterized the differences in response to dsRNA between species for each gene, using these cross-species bulk transcriptomics data. While some genes, such as those encoding the NF- $\kappa$ B subunits RELB and NFKB2, respond similarly across species, other genes respond differently in the primate and rodent clades (Fig. 1b, left). For example, IFI27 (a restriction factor against numerous viruses) is strongly upregulated in primates but not in rodents, whereas DAXX (an antiviral transcriptional repressor) exhibits the opposite behaviour.

Similarly, in our second experimental system, which consists of lipopolysaccharide (LPS)-stimulated mononuclear phagocytes from mouse, rat, rabbit, and pig (Fig. 1b, right), some genes responded similarly across species (for example, *Nfkb2*), whereas others were highly upregulated only in specific clades (for example, *Phlda1*).

To quantify transcriptional divergence in immune responses between species, we focused on genes that were differentially expressed during the stimulation (see Methods). For simplicity, we refer to these genes as ‘responsive genes’ (Fig. 1c). In this analysis, we study the subset of these genes with one-to-one orthologues across the studied species. There are 955 such responsive genes in dsRNA-stimulated human fibroblasts and 2,336 in LPS-stimulated mouse phagocytes. We define a measure of response divergence by calculating the differences between the fold-change estimates while taking the phylogenetic relationship into account (Methods, Supplementary Figs. 1–7 and Supplementary Table 4).

For subsequent analyses, we split the 955 genes that were responsive in fibroblasts into three groups on the basis of their level of response divergence: (1) high-divergence dsRNA-responsive genes (the top 25% of genes with the highest divergence values in response to dsRNA across the four studied species); (2) low-divergence dsRNA-responsive genes (the bottom 25%); and (3) genes with medium divergence across species (the middle 50%; Fig. 1c). We performed an analogous procedure for the 2,336 LPS-responsive genes in phagocytes. [Author: In normal English usage, ‘lowly’ is not the opposite of ‘highly’; therefore I have changed ‘highly divergent genes’ and ‘lowly divergent genes’ to ‘high-divergence genes’ and ‘low-divergence genes’, respectively; ok?]

### Promoter architecture of diverging genes

Next, we tested whether divergence in transcriptional responses is reflected in the conservation of promoter function and sequence. Using chromatin immunoprecipitation with sequencing (ChIP-seq), we profiled active histone marks in the fibroblasts of all species. The presence of trimethylation of lysine 4 on histone H3 (H3K4me3) in promoter regions of high-divergence genes was significantly [Author: We reserve ‘significantly’ to refer to statistical significance. If you are referring here to statistical significance, please give *P* value; otherwise, please replace with ‘substantially’ or similar; also where highlighted below.] less conserved between humans and rodents than was the presence of H3K4me3 in promoters of low-divergence genes (Extended Data Fig. 2).

We then used the human H3K4me3 ChIP–seq peaks to define active promoter regions of the responsive genes in human fibroblasts. The density of transcription factor binding motifs (TFBMs) was significantly higher in the active promoter regions of high-divergence genes than in low-divergence genes (Fig. 2a). Notably, when comparing the conservation of the core promoter regions in high- versus low-divergence dsRNA-responsive genes, we found that genes that diverge highly in response to dsRNA show higher sequence conservation in this region (Fig. 2b).

This unexpected discordance may be related to the fact that promoters of high- and low-divergence genes have distinctive architectures, associated with different constraints on promoter sequence evolution<sup>18,25,26</sup>. Notably, promoters containing TATA-box elements tend to have most of their regulatory elements in regions immediately upstream of the transcription start site (TSS). These promoters are thus expected to be more conserved. The opposite is true for CpG island (CGI)<sup>26,27</sup> promoters. Indeed, we found that TATA-boxes are associated with higher transcriptional divergence, while genes with CGIs diverge more slowly, both in fibroblasts and phagocytes (Fig. 2c; Extended Data Fig. 3). Thus, a promoter architecture enriched in TATA-boxes and depleted of CGIs is associated with higher transcriptional divergence, while entailing higher sequence conservation upstream of these genes<sup>18,26,27</sup>.

### **Cytokines diverge rapidly in immune response**

We next investigated whether different functional classes among responsive genes are characterized by varying levels of transcriptional divergence. To this end, we divided responsive genes into categories according to function (such as cytokines, transcriptional factors and kinases) or the processes in which they are known to be involved (such as apoptosis or inflammation).

Genes related to cellular defence and inflammation—most notably cytokines, chemokines and their receptors (hereafter ‘cytokines’)—tended to diverge in response significantly faster than genes involved in apoptosis or immune regulation (chromatin modulators, transcription factors, kinases and ligases) (Fig. 2d, e, Extended Data Fig. 4, Supplementary Fig. 1).

Cytokines also had a higher transcriptional range in response to immune challenge (a higher fold-change). Regressing the fold-change from the divergence estimates resulted in reduction of the relative divergence of cytokines versus other responsive genes, but the

difference still remained **significant** (Supplementary Fig. 2). Cytokine promoters are enriched in TATA-boxes (17% versus 2.5%,  $P = 1.1 \times 10^{-3}$ , Fisher's exact test) and depleted of CGIs (14% versus 69%,  $P = 1.6 \times 10^{-9}$ ), suggesting that this promoter architecture is associated both with greater differences between species (response divergence) and larger changes between conditions (transcriptional range).

### Cell-to-cell variability in immune response

Previous studies have shown that the innate immune response displays high variability across responding cells<sup>28,29</sup>. However, the relationship between cell-to-cell transcriptional variability and response divergence between species is not well understood.

To study heterogeneity in gene expression across individual cells, we performed single-cell RNA-seq in all species in a time course following immune stimulation. We estimated cell-to-cell variability quantitatively using an established measure for variability: distance to median (DM)<sup>30</sup>.

We found a clear trend in which genes that were highly divergent in response between species were also more variable in expression across individual cells within a species (Fig. 3a). The relationship between rapid divergence and high cell-to-cell variability held true in both the 955 dsRNA-responsive genes in fibroblasts and the 2,336 LPS-responsive genes in phagocytes. This can be observed across the stimulation time points and in different species (Extended Data Figs. 5, 6). We analysed in depth the relationship between transcriptional divergence and cell-to-cell variability by using additional immune stimulation protocols (Supplementary Figs. 8, 9), and different experimental and computational approaches (Extended Data Fig. 7, Supplementary Figs. 10–13). Notably, the trends we observed are not a result of technical biases due to low expression levels in either the bulk or the single-cell RNA-seq data (Supplementary Figs. 14, 15).

Next, we examined the relationship between the presence of promoter elements (CGIs and TATA-boxes) and a gene's cell-to-cell variability. Genes that are predicted to have a TATA-box in their promoter had **significantly** higher transcriptional variability, whereas CGI-containing genes tended to have lower variability (Fig. 3b), in agreement with previous findings<sup>31</sup>. Thus, both transcriptional variability between cells (Fig. 3b) and transcriptional divergence between species (Fig. 2c) are associated with the presence of specific promoter elements.

## Transcriptional variability of cytokines

We subsequently compared the response divergence across species with the transcriptional cell-to-cell variability of three groups of responsive genes with different functions: cytokines, transcription factors, and kinases and phosphatases (hereafter ‘kinases’; Fig. 3c, Extended Data Fig. 8). In contrast to kinases and transcription factors, many cytokines display relatively high levels of cell-to-cell variability (Extended Data Fig. 9), being expressed only in a small subset of responding cells (Extended Data Fig. 10). This has previously been reported for several cytokines<sup>29</sup>. For example, IFNB is expressed in only a small fraction of cells infected with viruses or challenged with various stimuli<sup>8,11,32</sup>. Here, we find that cells show high levels of variability in expression of cytokines from several families (for example, IFNB, CXCL10 and CCL2).

Cell-to-cell variability of cytokines remains relatively high in comparison to kinases and transcription factors during a time course of 2, 4 and 8 h after dsRNA stimulation of fibroblasts (Extended Data Fig. 9). This pattern is similar across species, and can also be observed in LPS-stimulated phagocytes (Extended Data Fig. 9). Thus, the high variability of cytokines and their expression in a small fraction of stimulated cells across all time points is evolutionarily conserved.

Cytokines tended to be co-expressed in the same cells, raising the possibility that their expression is coordinated (see Supplementary Information and Supplementary Fig. 16). We also identified genes whose expression was correlated with cytokines in human fibroblasts and showed that their orthologues are significantly co-expressed with cytokines in other species. This set is enriched with genes known to be involved in cytokine regulation (Supplementary Table 5).

As an example, we focused on the genes whose expression is positively correlated with the chemokine CXCL10 in at least two species (Fig. 3d). This set includes four cytokines co-expressed with CXCL10 (in purple), as well as known positive regulators of the innate immune response and cytokine production (in blue), such as the viral sensors IFIH1 (also known as MDA5) [Author: Changed to HUGO symbol per our style, ok? Changed in Fig. 3 also.] and RIG-I [Author: I could not find RIG-1 in the HUGO database. Do you mean mouse *Rig1* (regulation of Igh-1b 1) or *DDX58* (DEXD/H-box helicase 58, synonym *RIG-1*?]. This is in agreement with previous evidence that IFNB expression is limited to cells in which important upstream regulators are expressed at sufficiently high levels<sup>8,11,32</sup>. We show that this phenomenon of co-expression with upstream regulators

applies to a wide set of cytokines and is conserved across species. Notably, cytokines were co-expressed not only with their positive regulators but also with genes that are known to act as negative regulators of cytokine expression or cytokine signalling (in red), suggesting that cytokine expression and function is tightly controlled at the level of individual cells.

### The evolutionary landscape of innate immunity

Many immune genes, including several cytokines and their receptors, have been shown to evolve rapidly in coding sequence<sup>3,33</sup>. However, it is not known how divergence in coding sequence relates to transcriptional divergence in innate immune genes. Using the set of 955 dsRNA-responsive genes in fibroblasts, we assessed coding sequence evolution in the three subsets of low-, medium- and high-divergence genes (as defined in Fig. 1c).

We compared the rate at which genes evolved in their coding sequences with their response divergence by considering the ratio of non-synonymous (dN) to synonymous substitutions (dS). Genes that evolved rapidly in transcriptional response had higher coding sequence divergence (higher dN/dS values) than dsRNA-responsive genes with low response divergence (Fig. 4a).

Rapid gene duplication and gene loss have been observed in several important immune genes<sup>34–39</sup> and are thought to be a result of pathogen-driven pressure<sup>40,41</sup>. We therefore tested the relationship between a gene's divergence in response and the rate at which the gene's family has expanded and contracted in the course of vertebrate evolution. We found that transcriptionally divergent dsRNA-responsive genes have higher rates of gene gain and loss (Fig. 4b) and consequently are also evolutionarily younger (Fig. 4c, Supplementary Fig. 17).

Previous reports have suggested that proteins encoded by younger genes tend to have fewer protein–protein interactions (PPIs) within cells<sup>42</sup>. Indeed, we found that rapidly diverging genes tend to have fewer PPIs (Fig. 4d). Together, these results suggest that transcriptionally divergent dsRNA-responsive genes evolve rapidly through various mechanisms, including fast coding sequence evolution and higher rates of gene loss and duplication events, and that their products have fewer interactions with other cellular proteins than those of less divergent genes [Author: Correct as edited?].

The interaction between pathogens and the host immune system is thought to be an important driving force in the evolution of both sides. We therefore investigated the relationship between transcriptional divergence and interactions with viral proteins by

compiling a data set of known host–virus interactions in humans<sup>6,43,44</sup>. Notably, genes whose products had no known viral interactions showed higher response divergence than genes encoding proteins with viral interactions [Author: Correct as edited?] (Fig. 4e). Furthermore, the transcriptional divergence of genes targeted by viral immunomodulators<sup>45</sup>—viral proteins that subvert the host immune system—was lower still (Fig. 4e). These observations suggest that viruses have evolved to modulate the immune system by interacting with immune proteins that are relatively conserved in their response. Presumably, these genes cannot evolve away from viral interactions, unlike host genes that are less constrained<sup>46</sup>.

The summary of our results in Fig. 4f highlights the differences in both regulatory and evolutionary characteristics between cytokines and other representative dsRNA-responsive genes. Cytokines evolve rapidly through various evolutionary mechanisms and have higher transcriptional variability across cells. By contrast, genes that are involved in immune response regulation, such as transcription factors and kinases, are more conserved and less heterogeneous across cells. These genes encode proteins that have more interactions with other cellular proteins, [Author: Correct as edited?] suggesting that higher constraints are imposed on their evolution. This group of conserved genes is more often targeted by viruses, revealing a relationship between host–pathogen dynamics and the evolutionary landscape of the innate immune response.

## Discussion

Here, we have charted the evolutionary architecture of the innate immune response. We show that genes that diverge rapidly between species show higher levels of variability in their transcription across individual cells than genes that diverge more slowly [Author: Correct as edited?]. Both of these characteristics are associated with a similar promoter architecture, enriched in TATA-boxes and depleted of CGIs. Notably, such promoter architecture is also associated with the high transcriptional range of genes during the immune response. Thus, transcriptional changes between conditions (stimulated versus unstimulated), species (transcriptional divergence), and individual cells (cell–cell variability) may all be mechanistically related to the same promoter characteristics. In yeast, TATA-boxes are enriched in promoters of stress-related genes, displaying rapid transcriptional divergence between species and high variability in expression<sup>30,47</sup>. This finding suggests intriguing analogies between the mammalian immune and yeast stress responses—two systems that have been exposed to continuous changes in external stimuli during evolution.

We have also shown that genes involved in regulation of the immune response—such as transcription factors and kinases—are relatively conserved in their transcriptional responses. These genes might be under stronger functional and regulatory constraints, owing to their roles in multiple contexts and pathways, which would limit their ability to evolve. This limitation could represent an Achilles' heel that is used by pathogens to subvert the immune system. Indeed, we found that viruses interact preferentially with conserved proteins of the innate immune response. Cytokines, on the other hand, diverge rapidly between species, owing to their promoter architecture and because they have fewer constraints imposed by intracellular interactions or additional non-immune functions. We therefore suggest that cytokines represent a successful host strategy to counteract rapidly evolving pathogens as part of the host–pathogen evolutionary arms race.

Cytokines also display high cell–cell variability and tend to be co-expressed with other cytokines and cytokine regulators in a small subset of cells, and this pattern is conserved across species. As prolonged or increased cytokine expression can result in tissue damage<sup>48–50</sup>, restriction of cytokine production to only a few cells may enable a rapid, but controlled, response across the tissue to avoid long-lasting and potentially damaging effects.

**Online content** Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at

Received 24 August 2017; accepted 17 August 2018

1. Borden, E. C. *et al.* Interferons at age 50: past, current and future impact on biomedicine. *Nat. Rev. Drug Discov.* **6**, 975–990 (2007).
2. Iwasaki, A. A virological view of innate immune recognition. *Annu. Rev. Microbiol.* **66**, 177–196 (2012).
3. Nielsen, R. *et al.* A scan for positively selected genes in the genomes of humans and chimpanzees. *PLoS Biol.* **3**, e170 (2005).
4. Haygood, R., Babbitt, C. C., Fedrigo, O. & Wray, G. A. Contrasts between adaptive coding and noncoding changes during human evolution. *Proc. Natl Acad. Sci. USA* **107**, 7853–7857 (2010).
5. Fumagalli, M. *et al.* Signatures of environmental genetic adaptation pinpoint pathogens as the main selective pressure through human evolution. *PLoS Genet.* **7**, e1002355 (2011).

6. Enard, D., Cai, L., Gwennap, C. & Petrov, D. A. Viruses are a dominant driver of protein adaptation in mammals. *eLife* **5**, e12469 (2016).
7. Barreiro, L. B. & Quintana-Murci, L. From evolutionary genetics to human immunology: how selection shapes host defence genes. *Nat. Rev. Genet.* **11**, 17–30 (2010).
8. Zhao, M., Zhang, J., Phatnani, H., Scheu, S. & Maniatis, T. Stochastic expression of the interferon- $\beta$  gene. *PLoS Biol.* **10**, e1001249 (2012).
9. Avraham, R. *et al.* Pathogen cell-to-cell variability drives heterogeneity in host immune responses. *Cell* **162**, 1309–1321 (2015).
10. Shalek, A. K. *et al.* Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. *Nature* **510**, 363–369 (2014).
11. Hwang, S. Y. *et al.* Biphasic RLR-IFN- $\beta$  response controls the balance between antiviral immunity and cell damage. *J. Immunol.* **190**, 1192–1200 (2013).
12. Porritt, R. A. & Hertzog, P. J. Dynamic control of type I IFN signalling by an integrated network of negative regulators. *Trends Immunol.* **36**, 150–160 (2015).
13. Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. *Nat. Rev. Immunol.* **14**, 36–49 (2014).
14. Brinkworth, J. F. & Barreiro, L. B. The contribution of natural selection to present-day susceptibility to chronic inflammatory and autoimmune disease. *Curr. Opin. Immunol.* **31**, 66–78 (2014).
15. Kobayashi, K. S. & Flavell, R. A. Shielding the double-edged sword: negative regulation of the innate immune system. *J. Leukoc. Biol.* **75**, 428–433 (2004).
16. Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. *Int. Rev. Immunol.* **30**, 16–34 (2011).
17. Barreiro, L. B., Marioni, J. C., Blekhman, R., Stephens, M. & Gilad, Y. Functional comparison of innate immune signaling pathways in primates. *PLoS Genet.* **6**, e1001249 (2010).
18. Schroder, K. *et al.* Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. *Proc. Natl Acad. Sci. USA* **109**, E944–E953 (2012).

19. Shay, T. *et al.* Conservation and divergence in the transcriptional programs of the human and mouse immune systems. *Proc. Natl Acad. Sci. USA* **110**, 2946–2951 (2013).
20. Brawand, D. *et al.* The evolution of gene expression levels in mammalian organs. *Nature* **478**, 343–348 (2011).
21. Kalinka, A. T. *et al.* Gene expression divergence recapitulates the developmental hourglass model. *Nature* **468**, 811–814 (2010).
22. Khaitovich, P., Enard, W., Lachmann, M. & Pääbo, S. Evolution of primate gene expression. *Nat. Rev. Genet.* **7**, 693–702 (2006).
23. Levin, M. *et al.* The mid-developmental transition and the evolution of animal body plans. *Nature* **531**, 637–641 (2016).
24. Reilly, S. K. & Noonan, J. P. Evolution of gene regulation in humans. *Annu. Rev. Genomics Hum. Genet.* **17**, 45–67 (2016).
25. Tirosh, I., Weinberger, A., Carmi, M. & Barkai, N. A genetic signature of interspecies variations in gene expression. *Nat. Genet.* **38**, 830–834 (2006).
26. Haberle, V. & Lenhard, B. Promoter architectures and developmental gene regulation. *Semin. Cell Dev. Biol.* **57**, 11–23 (2016).
27. Lenhard, B., Sandelin, A. & Carninci, P. Metazoan promoters: emerging characteristics and insights into transcriptional regulation. *Nat. Rev. Genet.* **13**, 233–245 (2012).
28. Franz, K. M. & Kagan, J. C. Innate immune receptors as competitive determinants of cell fate. *Mol. Cell* **66**, 750–760 (2017).
29. Satija, R. & Shalek, A. K. Heterogeneity in immune responses: from populations to single cells. *Trends Immunol.* **35**, 219–229 (2014).
30. Newman, J. R. *et al.* Single-cell proteomic analysis of *S. cerevisiae* reveals the architecture of biological noise. *Nature* **441**, 840–846 (2006).
31. Faure, A. J., Schmiedel, J. M. & Lehner, B. Systematic analysis of the determinants of gene expression noise in embryonic stem cells. *Cell Syst.* **5**, 471–484.e474 (2017).
32. Rand, U. *et al.* Multi-layered stochasticity and paracrine signal propagation shape the type-I interferon response. *Mol. Syst. Biol.* **8**, 584 (2012).

33. Fumagalli, M. & Sironi, M. Human genome variability, natural selection and infectious diseases. *Curr. Opin. Immunol.* **30**, 9–16 (2014).
34. Johnson, W. E. & Sawyer, S. L. Molecular evolution of the antiretroviral TRIM5 gene. *Immunogenetics* **61**, 163–176 (2009).
35. Choo, S. W. *et al.* Pangolin genomes and the evolution of mammalian scales and immunity. *Genome Res.* **26**, 1312–1322 (2016).
36. Braun, B. A., Marcovitz, A., Camp, J. G., Jia, R. & Bejerano, G. Mx1 and Mx2 key antiviral proteins are surprisingly lost in toothed whales. *Proc. Natl Acad. Sci. USA* **112**, 8036–8040 (2015).
37. Xu, L. *et al.* Loss of RIG-I leads to a functional replacement with MDA5 in the Chinese tree shrew. *Proc. Natl Acad. Sci. USA* **113**, 10950–10955 (2016).
38. Sackton, T. B., Lazzaro, B. P. & Clark, A. G. Rapid expansion of immune-related gene families in the house fly, *Musca domestica*. *Mol. Biol. Evol.* **34**, 857–872 (2017).
39. Brunette, R. L. *et al.* Extensive evolutionary and functional diversity among mammalian AIM2-like receptors. *J. Exp. Med.* **209**, 1969–1983 (2012).
40. Malfavon-Borja, R., Wu, L. I., Emerman, M. & Malik, H. S. Birth, decay, and reconstruction of an ancient TRIMCyp gene fusion in primate genomes. *Proc. Natl Acad. Sci. USA* **110**, E583–E592 (2013).
41. Barber, M. F., Lee, E. M., Griffin, H. & Elde, N. C. Rapid evolution of primate type 2 immune response factors linked to asthma susceptibility. *Genome Biol. Evol.* **9**, 1757–1765 (2017).
42. Saeed, R. & Deane, C. M. Protein–protein interactions, evolutionary rate, abundance and age. *BMC Bioinformatics* **7**, 128 (2006).
43. Calderone, A., Licata, L. & Cesareni, G. VirusMentha: a new resource for virus-host protein interactions. *Nucleic Acids Res.* **43**, D588–D592 (2015).
44. Halehalli, R. R. & Nagarajaram, H. A. Molecular principles of human virus protein–protein interactions. *Bioinformatics* **31**, 1025–1033 (2015).
45. Pichlmair, A. *et al.* Viral immune modulators perturb the human molecular network by common and unique strategies. *Nature* **487**, 486–490 (2012).

46. Dyer, M. D., Murali, T. M. & Sobral, B. W. The landscape of human proteins interacting with viruses and other pathogens. *PLoS Pathog.* **4**, e32 (2008).
47. Tirosh, I. & Barkai, N. Two strategies for gene regulation by promoter nucleosomes. *Genome Res.* **18**, 1084–1091 (2008).
48. Crow, Y. J. & Manel, N. Aicardi-Goutières syndrome and the type I interferonopathies. *Nat. Rev. Immunol.* **15**, 429–440 (2015).
49. Hall, J. C. & Rosen, A. Type I interferons: crucial participants in disease amplification in autoimmunity. *Nat. Rev. Rheumatol.* **6**, 40–49 (2010).
50. Tisoncik, J. R. *et al.* Into the eye of the cytokine storm. *Microbiol. Mol. Biol. Rev.* **76**, 16–32 (2012).

**Acknowledgements** We thank N. Eling, M. Fumagalli, Y. Gilad, O. Laufman, A. Marcovitz, J. Marioni, K. Meyer, M. Muffato, D. Odom, O. Stegle, A. Stern, M. Stubbington, V. Svensson and M. Ward for discussions; G. Emerton, A. Jinat, L. Mamanova, K. Polanski, A. Fullgrabe, N. George, S. Barnett, R. Boyd, S. Patel and C. Gomez for technical assistance; the HipSci consortium for human fibroblast lines; and members of the Teichmann laboratory for support at various stages. This project was supported by ERC grants (ThDEFINE, ThSWITCH) and an EU FET-OPEN grant (MRG-GRAMMAR). T.H. was supported by an HFSP Long-Term Fellowship and by EMBO Long-Term and Advanced fellowships. V.P. is funded by Fondazione Umberto Veronesi.

**Reviewer information** *Nature* thanks L. Barreiro, I. Yanai and the other anonymous reviewer(s) for their contribution to the peer review of this work.

**Author contributions** T.H. and S.A.T. designed the project; T.H., X.C., R.J.M., R.R., N.K. and J.-E.P. [Author: Correct?] performed experiments with help from V.P., G.D. and F.A.V.B.; T.H., X.C., R.J.M., R.R., T.G. and J.H. analysed the data with help from G.N., L.B.-C. [Author: Correct?], G.T, A.N. and M.L.; J.F., E.S., P.V., I.K., M.D. and M.H. provided samples; S.A.T. supervised the project; T.H., R.R., N.K. and S.A.T. wrote the manuscript with input from all authors.

**Competing interests:** The authors declare no competing interests.

Additional information

**Extended data** is available for this paper at

**Supplementary information** is available for this paper at

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Correspondence and requests for materials** should be addressed to S.A.T. or T.H.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Author: Please ensure that the following information is included in the figure legends where relevant. Sample size (exact  $n$  number); a statement of replicability (how many times was experiment replicated in the laboratory); description of sample collection (clarify whether technical or biological replicates and include how many animals, litters, cultures, etc.); state the statistical test used and give  $P$  values; define centre values (median or average) and error bars. For figures/images that are reproduced or adapted from a third party, it is important that you confirm that permission has been obtained and that appropriate acknowledgement of the copyright holder is given.]

**Fig. 1 | Response divergence across species in innate immune response.** **a**, Study design. Left, primary dermal fibroblasts from mouse, rat, human and macaque stimulated with dsRNA or controls. Samples were collected for bulk and single-cell RNA-seq and ChIP-seq. Right, primary bone marrow-derived mononuclear phagocytes from mouse, rat, rabbit and pig stimulated with LPS or controls. Samples were collected for bulk and single-cell RNA-seq. **b**, Left, fold-change (FC) in dsRNA stimulation in fibroblasts for sample genes across species (edgeR exact test, based on  $n = 6, 5, 3, 3$  individuals from human, macaque, rat and mouse, respectively). Right, fold-change in LPS stimulation in phagocytes for sample genes across species (Wald test implemented in DESeq2, based on  $n = 3$  individuals from each species). FDR-corrected  $P$  values are shown ( $***P < 0.001$ ,  $**P < 0.01$ ,  $*P < 0.05$ ). **c**, Top, estimating each gene's level of cross-species divergence in transcriptional response to dsRNA stimulation in fibroblasts. Using differential expression analysis, fold-change in dsRNA response was assessed for each gene in each species. We identified 1,358 human genes as differentially expressed (FDR-corrected  $q < 0.01$ ), of which 955 had one-to-one orthologues across the four studied species. For each gene with one-to-one orthologues across all species, a response divergence measure was estimated using: response divergence =  $\log[1/4 \times \sum_{i,j} (\log[\text{FC primate}_i] - \log[\text{FC rodent}_j])^2]$ . [Author: Equations have been rekeyed, please check carefully.] Genes were grouped into low, medium and high divergence according to their response divergence values for subsequent analysis. Bottom, estimating each gene's level of cross-species divergence in LPS response in mononuclear phagocytes. A response divergence measure was estimated using: response divergence =  $\log[1/3 \times \sum_j (\log[\text{FC pig}] - \log[\text{FC glires}_j])^2]$  (where glires are mouse, rat and rabbit).

**Fig. 2 | Transcriptionally divergent genes have unique functions and promoter architectures.** **a**, TFBM density in active promoters and response divergence. For each gene

studied in fibroblast dsRNA stimulation, the total number of TFBM matches in its H3K4me3 histone mark was divided by the length of the mark (human marks were used;  $n = 879$  differentially expressed genes with ChIP-seq data). High-divergence genes have higher TFBM density than low-divergence genes (one-sided Mann-Whitney test). **b**, Promoter sequence conservation and response divergence in fibroblast dsRNA stimulation. Sequence conservation values are estimated with phyloP7 for 500 base pairs upstream of the TSS of the human gene. Mean conservation values of each of the 500 base pairs upstream of the TSS are shown for high-, medium- and low-divergence genes ( $n = 840$  genes). Genes that are highly divergent have higher sequence conservation (one-sided Kolmogorov-Smirnov test). The 95% confidence interval for predictions from a linear model computed by `geom_loess` function is shown in grey. **c**, Comparison of divergence in response of genes with and without a TATA-box and CGIs in fibroblast dsRNA stimulation and phagocyte LPS stimulation. TATA-box matches and CGI overlaps were computed with respect to the TSS of human genes in fibroblasts ( $n = 955$  genes), and to the TSS of mouse genes in phagocytes ( $n = 2,336$ ). **d**, Distributions of divergence values of 9,753 expressed genes in fibroblasts, 955 dsRNA-responsive genes and different functional subsets of the dsRNA-responsive genes (each subset is compared with the set of 955 genes using a one-sided Mann-Whitney test and FDR-corrected  $P$  values are shown). **e**, Distributions of divergence values of 6,619 expressed genes in phagocytes, 2,336 LPS-responsive genes and different functional subsets of the LPS-responsive genes (each subset is compared with the set of 2,336 genes using a one-sided Mann-Whitney test and FDR-corrected  $P$  values are shown). Violin plots show the kernel probability density of the data. Boxplots represent the median, first quartile and third quartile with lines extending to the furthest value within 1.5 of the inter-quartile range (IQR).

**Fig. 3 | Cell-cell variability in immune response corresponds to response divergence. a**, Comparison of divergence in response across species with transcriptional variability between individual cells. Top, fibroblast dsRNA stimulation (variability measured in  $n = 55$  human cells, following 4 h dsRNA stimulation). Bottom, phagocyte LPS stimulation (variability measured in  $n = 3,293$  mouse cells, following 4 h LPS stimulation). Genes classified as high-, medium- or low-divergence according to level of response divergence. Cell-cell variability values of high-divergence genes were compared with those of low-divergence genes (one-sided Mann-Whitney test). **b**, Comparison of cell-cell variability of genes with and without a TATA-box and CGI, in fibroblast dsRNA stimulation and phagocyte LPS stimulation (one-sided Mann-Whitney test). Cell-cell variability values are from DM estimations of human

fibroblasts stimulated with dsRNA for 4 h ( $n = 55$  cells) and from mouse phagocytes stimulated with LPS for 4 h ( $n = 3,293$  cells). **c**, Scatter plot showing divergence in response to dsRNA in fibroblasts across species and transcriptional cell–cell variability in human cells following 4 h of dsRNA stimulation ( $n = 684$  dsRNA-responsive genes). Purple, cytokines; green, transcription factors; beige, kinases. The distributions of divergence and variability values of these groups are shown above and to the right of the scatter plot, respectively. **d**, A network showing genes that correlate positively in expression with the chemokine *CXCL10* across cells (Spearman correlation,  $\rho > 0.3$ ), in at least two species, following dsRNA treatment in fibroblasts (based on  $n = 146, 74, 175$  and  $170$  human, macaque, rat and mouse cells, respectively). Purple, cytokines; red, positive regulators of cytokine expression; blue, negative regulators. Colours of lines [Author: Correct as edited?], from light to dark grey, reflect the number of species in which this pair of genes was correlated. Boxplots represent the median, first quartile and third quartile with lines extending to the furthest value within  $1.5 \times \text{IQR}$ . [Author: LGP2 changed to DHX58 (HUGO symbol) per our style, ok? Also FAM46A changed to TENT5A.]

**Fig. 4 | Relationship of response divergence and other evolutionary modes.** **a–d**, dsRNA-responsive genes in fibroblasts are divided by level of response divergence into three groups, as in Fig. 1c. **a**, Coding sequence divergence, as measured using dN/dS values across 29 mammals. Higher dN/dS values denote faster coding sequence evolution ( $n = 567$  genes). **b**, Rate at which genes were gained and lost within the gene family across the vertebrate clade (plotted as  $-\log P$ ). Higher values denote faster gene gain and loss rate ( $n = 955$  genes). **c**, Evolutionary age (estimated with Panther7 phylogeny and Wagner reconstruction algorithm). Values denote the branch number with respect to human (distance from human in the phylogenetic tree); higher values indicate greater age ( $n = 931$  genes). **d**, Number of known physical interactions with other cellular proteins ( $n = 955$  genes). **e**, Distribution of transcriptional response divergence values among dsRNA-responsive genes whose protein products do not interact with viruses, interact with at least one virus, or interact with viral immunomodulators ( $n = 648, 377$  and  $25$  genes, respectively). **a–e**, One-sided Mann–Whitney tests. **f**, A scaled heatmap showing values of response divergence (as in Fig. 1c), cell–cell variability (as in Fig. 3a), coding sequence divergence (dN/dS values, as in Fig. 4a), gene age (as in Fig. 3c; younger genes have darker colours), number of cellular PPIs (as in Fig. 4d) and number of host–virus interactions (as in Fig. 4e), for example genes from three functional groups: cytokines, transcription factors, and kinases. Values are shown in a

normalized scale between 0 and 100, with the gene with the highest value assigned a score of 100. Missing values are shown in white. Boxplots represent the median, first quartile and third quartile with lines extending to the furthest value within  $1.5 \times \text{IQR}$ . Violin plots show the kernel probability density of the data.

[Author: Please ensure that the following information is provided in the Methods section where relevant. Animal experiments require: statement about randomization; statement about blinding; statement of sex, age, species and strain of animals; statement of IRB approval for live vertebrate experimentation. For experiments involving humans: statement of IRB approval; statement of informed consent; statement of consent to publish any photos included in figures. Randomized clinical trials require trial registration. We recommend that detailed protocols are deposited in Protocol Exchange, or a similar repository. If custom computer code has been used and is central to the conclusions of this paper, please insert a section into the Methods titled ‘Code availability’ and indicate within this section whether and how the code can be accessed, including any restrictions to access.]

[Author: We assume no power analysis was done to estimate sample size; per our reporting guidelines we will include the statement ‘No statistical methods were used to predetermine sample size.’ Please edit if appropriate.]

[Author: In order to address the issue of cell line misidentification and cross-contamination, for any cell lines mentioned in the paper please provide source of the cell lines and indicate whether the cell lines have been correctly identified/authenticated (if so, by what methods). Also, please state whether cell lines have been tested for mycoplasma contamination.]

[Author: We assume there was no randomization; per our reporting guidelines, we will include the statement “The experiments were not randomized”. Also, we assume that there was no blinding; per our reporting guidelines, we will include the statement “The investigators were not blinded to allocation during experiments and outcome assessment”. Please edit either of these statements if necessary.]

## **METHODS**

### **Ethical compliance**

This project was approved by the Wellcome Sanger Institute Animal Welfare and Ethical Review Body, and complied with all relevant ethical regulations regarding animal research and human studies. Human cells were obtained from the Hipsi project<sup>51</sup>, where they were collected from volunteers recruited from the NIHR Cambridge BioResource (written consent

was given). Human skin profiling was performed in accordance with protocols approved by the Newcastle Research Ethics Committee (REC approval 08/H0906/95+5). Macaque skin samples were obtained from animals assigned to unrelated non-infectious studies, provided by Public Health England's National Infection Service in accordance with Home Office (UK) guidelines and approved by the Public Health England Ethical Review Committee under an appropriate UK Home Office project license. **[Author: We have only two levels of subheading in Methods: Bold (separate line) and italic (run-on). Please check that you are happy with how I have formatted your headings.]**

### **Cross-species dermal fibroblast stimulation with dsRNA and IFN $\beta$**

*Tissue culture.* We cultured primary dermal fibroblasts from low passage cells (below 10) that originated from females from four different species (human (European ancestry), rhesus macaque, C57BL/6 (black 6) mouse and brown Norway rat). All skin samples were taken from shoulders. Stimulation experiments and library preparations were done in identical conditions across all species and for all genomics techniques. Details on the numbers of individuals used in each technique are listed in each technique's section and in Supplementary Table 1.

Human cells were obtained from the Hipsi project<sup>51</sup> (<http://www.hipsi.org/>). Rhesus macaque cells were extracted from skin tissues that were incubated for 2 h with 0.5% collagenase B (Roche; 11088815001) after mechanical processing, and then filtered through 100- $\mu$ m strainers before being plated and passaged before cryo-banking. Rodent cells were obtained from PeliBiotech where they were extracted using a similar protocol. In vitro cultured fibroblasts from all four species resemble a particular in vivo cluster of dermal fibroblasts (see Supplementary Information).

Prior to stimulation, cells were thawed and grown for several days in ATCC fibroblast growth medium (Fibroblast Basal Medium (ATCC, ATCC-PCS-201-030) with Fibroblast Growth Kit-Low serum (ATCC, PCS-201-041) (supplemented with Primocin (Invivogen, ant-pm-1) and penicillin/streptomycin (Life Technologies, Cat. Code: 15140122))—a controlled medium that has proven to provide good growing conditions for fibroblasts from all species, with slightly less than 24 h doubling times. About 18 h before stimulation, cells were trypsinized, counted and seeded into 6-well plates (100,000 cells per well). Cells were stimulated as follows: (1) stimulated with 1  $\mu$ g/ml high-molecular weight poly I:C (Invivogen, Cat. Code: tlr1-pic) transfected with 2  $\mu$ g/ml Lipofectamin 2,000 (ThermoFisher,

Cat Number 11668027); (2) mock transfected with Lipofectamin 2,000; (3) stimulated with 1,000 IU of IFNB for 8 h (human IFNB: 11410-2 (for human and macaque cells); rat IFNB: 13400-1; mouse IFNB: 12401-1; all IFNs were obtained from PBL, and had activity units based on similar virological assays); or (4) left untreated. Interferon stimulation was used as a control, to study how genes that were upregulated in the secondary wave of the innate immune response diverge between species.

Additional human and mouse samples were stimulated with 1,000 IU of cross-mammalian IFN (CMI, or Universal Type I IFN Alpha, PBL, 11200-1). The latter stimulation was done to assess the effects of species-specific and batch-specific IFNB.

In all of the above-mentioned stimulations, we used a longer time course for single-cell RNA-seq than for bulk RNA-seq, for two main reasons: (1) in the bulk, we chose to focus on one main stimulation time point for simplicity and to obtain an intuitive fold-change between stimulated and unstimulated conditions; (2) in single cells, when studying cell-cell variability, we chose to profile, in addition to the main stimulation time point, cells in earlier and later stages of the response. This is important for studying how the dynamics and magnitude of the response affect gene expression variability between responding cells.

The poly I:C we used tested negative for the presence of bacterial beta-endotoxin using a coagulation test (PYROGENT Plus, 0.06 EU/ml sensitivity, N283-06).

*Bulk RNA sequencing: library preparation and sequencing.* For bulk transcriptomics analysis, cells **[Author: Correct as edited? Or 'cells from individuals']** from different species were grown in parallel and stimulated with dsRNA, IFNB (and cross-mammalian IFN) and their respective controls. In total, samples from 6 humans, 6 macaques, 3 mice and 3 rats were used. Total RNA was extracted using the RNeasy Plus Mini kit (Qiagen, 74136), using QIAcube (Qiagen). RNA was then measured using a Bioanalyzer 2100 (Agilent Technologies), and samples with RIN < 9 were excluded from further analysis (one macaque sample stimulated with poly I:C and its control).

Libraries were produced using the Kapa Stranded mRNA-seq Kit (Kapa Biosystems, Kit code: KK8421). The Kapa library construction protocol was modified for automated library preparation by Bravo (Agilent Technologies). cDNA was amplified in 13 PCR cycles, and purified using Ampure XP beads (Beckman Coulter, A63882) (1.8× volume) using Zephyr (Perkin Elmer). Pooled samples were sequenced on an Illumina HiSeq 2500 instrument, using paired-end 125-bp reads.

*ChIP-seq: library preparation and sequencing.* Samples from three individuals from each of the four species were grown and stimulated (with poly I:C for 4 h or left untreated, as described above) in parallel to samples collected for bulk RNA-seq. Following stimulation, samples were crosslinked in 1% HCHO (prepared in 1× DPBS) at room temperature for 10 min, and HCHO was quenched by the addition of glycine at a final concentration of 0.125 M. Cells were pelleted at 4 °C at 2,000g, washed with ice-cold 1× DPBS twice, and snap-frozen in liquid nitrogen. Cell pellets were stored at –80 °C until further stages were performed. ChIPmentation was performed according to version 1.0 of the published protocol<sup>52</sup> with a few modifications (see additional details in Supplementary Methods).

Library preparation reactions contained the following reagents: 10 µl purified DNA (from the above procedure), 2.5 µl PCR Primer Cocktails (Nextera kit, Illumina, FC-121-1030), 2.5 µl N5xx (Nextera index kit, Illumina FC-121-1012), 2.5 µl N7xx (Nextera index kit, Illumina, FC-121-1012), 7.5 µl NPM PCR Master Mix (Nextera kit, Illumina, FC-121-1030). PCR cycles were as follows: 72 °C, 5 min; 98 °C, 2 min; [98 °C, 10 s, 63 °C, 30 s, 72 °C, 20 s] × 12; 10 °C hold.

Amplified libraries were purified by double AmpureXP bead purification: first with 0.5× bead ratio, keep supernatant, second with 1.4× bead ratio, keep bound DNA. Elution was done in 20 µl Buffer EB (QIAGEN).

One microlitre of library was run on a Bioanalyzer (Agilent Technologies) to verify normal size distribution. Pooled samples were sequenced on an Illumina HiSeq 2000 instrument, using paired-end 75-bp reads.

*Single-cell RNA-seq: flow cytometry.* For scRNA-seq, we performed two biological replicates, with each replicate having one individual from each of the four studied species. A time course of dsRNA stimulation of 0, 4, and 8 h was used in one replicate (divided into two technical replicates), while the second replicate included a time course of 0, 2, 4, and 8 h. Poly I:C transfection was done as described above. In the case of sorting with IFNLUX, we used rhodamine-labelled poly I:C.

Cells were sorted with either Beckman Coulter MoFlo XDP (first replicate) or Becton Dickinson INFLUX (second replicate) into wells containing 2 µl lysis buffer (1:20 solution of RNase Inhibitor (Clontech, 2313A) in 0.2% v/v Triton X-100 (Sigma-Aldrich, T9284)), spun down and immediately frozen at –80 °C.

When sorting with MoFlo, a pressure of 15 psi was used with a 150- $\mu$ m nozzle, using the ‘Single’ sort purity mode. Dead or late-apoptosis cells were excluded using propidium iodide at 1  $\mu$ g/ml (Sigma, Cat Number P4170) and single cells were selected using FSC W versus FSC H. When sorting with INFLUX, a pressure of 3 psi was used with a 200- $\mu$ m nozzle, with the ‘single’ sort mode. Dead or late-apoptosis cells were excluded using 100 ng/ml DAPI (4',6-diamidino-2-phenylindole) (Sigma, D9542). DAPI was detected using the 355-nm laser (50 mW), using a 460/50 nm bandpass filter. Rhodamine was detected using the 561-nm laser (50mW), using a 585/29 nm bandpass filter. Single cells were collected using FSC W versus FSC H.

*Library preparation from full-length RNA from single cells and sequencing.* Sorted plates were processed according to the Smart-seq2 protocol<sup>53</sup>. Oligo-dT primer (IDT), dNTPs (ThermoFisher, 10319879) and ERCC RNA Spike-In Mix (1:25,000,000 final dilution, Ambion, 4456740) were added to each well, and reverse transcription (using 50 U SmartScribe, Clontech, 639538) and PCR were performed following the original protocol with 25 PCR cycles. cDNA libraries were prepared using Nextera XT DNA Sample Preparation Kit (Illumina, FC-131-1096), according to the protocol supplied by Fluidigm (PN 100-5950 B1). Quality Checks on cDNA were done using a Bioanalyser 2100 (Agilent Technologies). Libraries were quantified using the LightCycler 480 (Roche), pooled and purified using AMPure XP beads (Beckman Coulter) with Hamilton 384 head robot (Hamilton Robotics). Pooled samples were sequenced on an Illumina HiSeq 2500 instrument, using paired-end 125-bp reads.

*Cross-species response divergence: read mapping to annotated transcriptome.* For bulk RNA-seq samples, adaptor sequences and low-quality score bases were first trimmed using Trim Galore (version 0.4.1) (with the parameters ‘-paired-quality 20-length 20 -e 0.1-adaptor AGATCGGAAGAGC’). Trimmed reads were mapped and gene expression was quantified using Salmon (version 0.6.0)<sup>54</sup> with the following command: ‘salmon quant -i [index\_file\_directory] -l ISR -p 8-biasCorrect-sensitive-extraSensitive -o [output\_directory] -1 -g [ENSEMBL\_transcript\_to\_gene\_file]-useFSPD-numBootstraps 100’. Each sample was mapped to its respective species’ annotated transcriptome (downloaded from ENSEMBL, version 84: GRCh38 for human, MMUL\_1 for macaque, GRCm38 for mouse, Rnor\_6.0 for rat). We included only the set of coding genes (\*.cdna.all.fa files). We removed annotated secondary haplotypes of human genes by removing genes with ‘CHR\_HSCHR’.

*Quantifying differential gene expression in response to dsRNA.* To quantify differential gene expression between treatment and control for each species and for each treatment separately, we used edgeR (version 3.12.1)<sup>55</sup> using the rounded estimated counts from Salmon. This was done only for genes that had a significant level of expression in at least one of the four species (TPM >3 [Author: Please define TPM]) in at least  $N - 1$  libraries, where  $N$  is the number of different individuals we have for this species with libraries that passed quality control). Differential expression analysis was performed using the edgeR exact test, and  $P$  values were adjusted for multiple testing by estimating the false discovery rate (FDR).

*Conservation and divergence in response: fold-change-based phylogeny.* We compared the overall change in response to treatment (dsRNA or IFNB) between pairs of species, by computing the Spearman correlation of the fold-change in response to treatment across all one-to-one orthologues that were expressed in at least one species (Extended Data Fig. 1a–h). Fold-change was calculated with edgeR, as described above. Spearman correlations of all expressed genes appear in grey. Correlations of the subset of differentially expressed genes (genes with FDR-corrected  $P < 0.01$  in at least one of the compared species) appear in black.

In Extended Data Fig. 1a–c, we show comparisons in response to dsRNA. In Extended Data Fig. 1d–f, we show comparisons in response to IFNB, which we use here to study the similarity of the secondary immune response between species.

We constructed a tree based on a gene's change in expression in response to dsRNA and to IFNB, using expressed genes that had one-to-one orthologues across all four species and were expressed in at least one species in at least one condition (Extended Data Fig. 1i). We used hierarchical clustering, with the hclust command from the stats R package, with the distance between samples computed as  $1 - \rho$ , where  $\rho$  is the pairwise Spearman correlation between each pair of species mentioned above (a greater similarity, reflected in a higher correlation, results in a smaller distance) and 'average' as the clustering method.

The above-mentioned analyses focus on one-to-one orthologues between the compared species. In Supplementary Table 6, we quantify the similarity in response between species (based on Spearman correlations) when adding genes with one-to-many orthologues.

*Quantifying gene expression divergence in response to immune challenge.* To quantify transcriptional divergence in immune response between species, we focus on genes that have annotated one-to-one orthologues across the studied species (human, macaque, mouse and rat). 9,753 of the expressed genes have annotated one-to-one orthologues in all four species,

out of which 955 genes are differentially expressed in human in response to dsRNA treatment (genes with an FDR-corrected  $P < 0.01$ ).

We define a measure of response divergence (based on a previous study<sup>56</sup>) by calculating the differences between the fold-change estimates across the orthologues: response divergence =  $\log[1/4 \times \sum_{i,j} (\log[\text{FC primate}_i] - \log[\text{FC rodent}_j])^2]$ . This measure takes into account the structure of the phylogeny, and gives a relative measure of divergence in response across all genes with one-to-one orthologues.

To consider differences between species, we focus on between-clade differences (primates versus rodents), rather than on within-clade differences. In this way, we map the most significant macro-evolutionary differences along the longest branches of our four-species phylogeny. In addition, averaging within clades acts as a reduction of noise<sup>56</sup>.

We compared this divergence measure to two other measures that use models (and incorporate both between- and within-clade divergence) and found a strong correlation between the divergence estimates across the three approaches (Supplementary Figs. 3, 4).

In most of the subsequent analyses, we focus on the 955 dsRNA-responsive genes: genes that were differentially expressed in response to dsRNA (genes that have an FDR-corrected  $P < 0.01$  in human, and have annotated one-to-one orthologues in the other three species). For some of the analyses, we split these 955 genes based on quartiles, into genes with high, medium and low divergence (Fig. 1c).

We also studied how imprecisions in the fold-change estimates affected the response divergence estimates and subsequent analyses (Supplementary Figs. 5, 6).

*Comparison of response divergence between different functional groups.* To compare the divergence rates between sets of dsRNA-responsive genes that have different functions in the innate immune response, we split these 955 genes into the following functional groups (all groups are mutually exclusive, and any gene that belongs to two groups was excluded from the latter group; human gene annotations were used).

We first grouped genes by annotated molecular functions: viral sensors (genes that belong to one of the GO categories: GO:0003725 (dsRNA binding), GO:0009597 (detection of virus), and GO:0038187 (pattern recognition receptor activity)); cytokines, chemokines and their receptors (GO:0005125 (cytokine activity), GO:0008009 (chemokine activity), GO:0004896 (cytokine receptor activity), and GO:0004950 (chemokine receptor activity));

transcription factors (taken from the Animal Transcription Factor DataBase (version 2.0)<sup>57</sup>); chromatin modulators (GO:0016568 (chromatin modification), GO:0006338 (chromatin remodelling), GO:0003682 (chromatin binding), and GO:0042393 (histone binding)); kinases and phosphatases (GO:0004672 (protein kinase activity) and GO:0004721 (phosphoprotein phosphatase activity)); ligases and deubiquitinases (GO:0016579 (protein deubiquitination), GO:0004842 (ubiquitin-protein transferase activity) and GO:0016874 (ligase activity)); and other enzymes (mostly involved in metabolism rather than regulation: GO:0003824 (catalytic activity)). The divergence response values of these functional subsets were compared to the entire group of 955 dsRNA-responsive genes (Fig. 2d, e).

Next, we grouped genes by biological processes that are known to be important in the innate immune response: antiviral defence (GO:0051607 (defence response to virus)); inflammation (GO:0006954 (inflammatory response)); apoptosis (GO:0006915 (apoptotic process)); and regulation (GO annotations related to regulation of innate immune response pathways include only few genes. We thus used as the group of genes related to regulation, the merged group of genes that are annotated as transcription factors, chromatin modulators, kinases and phosphates or ligases and deubiquitinases, since all these groups include many genes that are known to regulate the innate immune response.)

Gene lists belonging to the mentioned GO annotations were downloaded using QuickGo<sup>58</sup>. The distribution of response divergence values for each of the functional groups was compared with the distribution of response divergence of the entire set of dsRNA-responsive genes. Cytokines, chemokines and their receptors are merged in Figs. 2d, e, 3c. Analogous comparisons of functional groups in IFNB response (with 841 IFNB-responsive genes) are shown in Supplementary Fig. 1. See additional analyses in Supplementary Information.

*Conservation of active chromatin marks analysis: alignment and peak calling of ChIP-seq reads.* ChIP-seq reads were trimmed using trim\_galore (version 0.4.1) with ‘-paired-trim1-nextera’ flags. The trimmed reads were aligned to the corresponding reference genome (hg38 for human, rheMac2 for macaque, mm10 for mouse, rn6 for rat; all these genomes correspond to the transcriptomes used for RNA-seq mapping) from the UCSC Genome Browser<sup>59</sup> using bowtie2 (version 2.2.3) with default settings<sup>60</sup>. In all four species, we removed the Y chromosome. In the case of human, we also removed all alternative haplotype chromosomes. Following alignment, low-confident mapped and improperly paired reads were removed by samtools<sup>61</sup> with ‘-q 30 -f 2’ flags.

Enriched regions (peaks) were called using MACS2 (v 2.1.1)<sup>62</sup> with a corrected  $P$  value cutoff of 0.01 with '-f BAMPE -q 0.01 -B-SPMR' flags, using input DNA as control. The genome sizes (the argument for '-g' flag) used were 'hs' for human, 'mm' for mouse,  $3.0 \times 10^9$  for macaque and  $2.5 \times 10^9$  for rat. Peaks were considered reproducible when they were identified in at least two of the three biological replicates and overlapped by at least 50% of their length (non-reproducible peaks were excluded from subsequent analyses). Reproducible peaks were then merged to create consensus peaks from overlapping regions of peaks from the three replicates by using mergeBed from the bedtools suite<sup>63</sup>.

*Gene assignment and conservation of active promoters and enhancers.* We subsequently linked human peaks with the genes they might be regulating as follows: H3K4me3 consensus peak was considered the promoter region of a given gene if its centre was between 2 kb upstream and 500 bp downstream of the annotated TSS of the most abundantly expressed transcript of that gene.

Similarly, H3K27ac was considered the enhancer region of a given gene if its centre was in a distance above 1 kb and below 1 Mb, and there was no overlap (of 1 bp or more) with any H3K4me3 peak.

In each case where, based on the distance criteria, more than a single peak was linked to a gene (or more than a single gene was linked to a peak), we took only the closest peak–gene pair (ensuring that each peak will have up to one gene and vice versa).

To compare active promoters and enhancers between species, we excluded any human peak that could not be uniquely mapped to the respective region in the other species. This was done by looking for syntenic regions of human peaks in the other three species by using liftOver<sup>64</sup>, and removing peaks that had either unmapped regions or more than one mapped region in the compared species. We considered syntenic regions with at least 10% sequence similarity between the species (minMatch = 0.1), with a minimal length (minSizeQ and minSizeT) corresponding to the length of the shortest peak (128 bp in H3K4 and 142 bp in H3K27).

We defined an active human promoter or enhancer as conserved if a peak was identified in the corresponding region of the other species (we repeated this analysis by comparing human with each of the other three species separately). We compared the occurrence of conserved promoters and enhancers in genes that are highly divergent in response to dsRNA with low-divergence genes, and used Fisher's exact test to determine the

statistical significance of the observed differences between high- and low-divergence genes (Extended Data Fig. 2).

*Promoter sequence analysis.* To calculate the total number of transcription factor binding motifs in a gene's active promoter region, we downloaded the non-redundant JASPAR core motif matrix (pfm Vertebrates.txt) from the JASPAR 2016 server<sup>65</sup> and searched for significant matches for these motifs using FIMO<sup>66</sup> in human H3K4me3 peaks. The TFBM density of peaks was calculated by dividing the total number of motif matches in a peak by the peak's length. TFBM density values in human H3K4me3 peaks linked with high- and low-divergence genes were compared (Fig. 2a).

PhyloP7 values were used to assess promoter sequence conservation<sup>67</sup>. Sequence conservation quantification was performed by taking the estimated nucleotide substitution rate for each nucleotide along the promoter sequence (500 bp upstream of the TSS of the relevant human gene). When several annotated transcripts existed, the TSS of the most abundantly expressed transcript was used (based on bulk RNA data). The substitution rate values from all genes were aligned, based on their TSS position, and a mean for each of the 500 positions was calculated separately for the group of genes with high, medium and low response divergence. The two-sample Kolmogorov–Smirnov test was used to compare the paired distribution of rates between the means of the high-divergence and low-divergence sets of genes. To plot the mean values of the three sets of divergent genes, the geom\_smooth function from the ggplot2 R package was used with default parameters (with loess as the smoothing method) (Fig. 2b).

Human CGI annotations were downloaded from the UCSC genome table browser (hg38), and CGI genes were defined as those with a CGI overlapping their core promoter (300 bp upstream of the TSS reference position, and 100 bp downstream of it, as suggested previously<sup>18</sup>). Genes were defined as having a TATA box if they had a significant match to the Jaspas TATA box matrix (MA0108.1) in the 100 bp upstream of their TSS by FIMO<sup>66</sup> with default settings (we used a 100 bp window owing to possible inaccuracies in TSS annotations). We note that only 28 out of 955 dsRNA-responsive genes had a matching TATA-box motif in this region. For both TATA and CGI analyses, the promoter sequences of the human orthologues were used.

*Cell-to-cell transcriptional variability analysis: read mapping and quality control of scRNA-seq (full-length RNA).* Gene expression was quantified in a manner similar to the

quantification for bulk transcriptomics libraries described above. Low-quality cells were filtered using quality control criteria (cells with at least 100,000 mapped reads, with at least 2,000 expressed genes with TPM > 3, with ERCC < 10% and MT < 40%). **[Author: Please define ERCC and MT]** This quality control filtering resulted in 240 cells from a first biological replicate, including two technical replicates (with a time course of 0, 4, 8 h). In a second larger biological replicate (with a dsRNA stimulation time course of 0, 2, 4, 8 h), 728 cells passed quality control. Results throughout the manuscript relate to the second cross-species biological replicate in which a higher proportion of cells passed QC, and the lower-quality first replicate data were not considered further.

*Cell–cell variability analysis.* To quantify the biological cell–cell variability of genes, we applied the DM (Distance to Median) approach—an established method, which calculates the cell–cell variability in gene expression while accounting for confounding factors such as gene expression level<sup>30</sup>. This is done by first filtering out genes that are expressed at low levels: for Smart-seq2 data we included only genes that had an average expression of at least 10 size-factor normalized reads (except for **Extended Data Fig. 9a**, in which we reduced the threshold to 5, to allow a larger number of genes to be included in the comparisons). This procedure was done to filter genes that displayed higher levels of technical variability between samples owing to low expression. Second, to account for gene expression level, the observed cell–cell variability of each gene was compared with its expected variability, based on its mean expression across all samples and in comparison with a group of genes with similar levels of mean expression. This DM value is also corrected by gene length (in the case of Smart-seq2 data), yielding a value of variability that can be compared across genes regardless of their length and mean expression values<sup>68</sup>. As a second approach, we used BASiCS<sup>69,70</sup> (see Supplementary Information).

We note that the relationship observed in **Fig. 3a** between response divergence and cell–cell variability is not an artefact, stemming from differences in expression levels. (A) With respect to cell–cell variability, a gene’s expression level is controlled for by DM calculations, where expression level is regressed by using a running median (Supplementary Fig. 14). (B) Similarly, we can regress the expression level measured in bulk RNA-seq from the quantified response divergence by subtracting the running median of expression from the divergence estimates. When repeating the analysis comparing cell–cell variability versus regressed response divergence, the relationship between the two is maintained (Supplementary Fig. 15).

*Cytokine co-expression analysis.* For the chemokine CXCL10, we built a network (using CytoScape<sup>71</sup>) of genes that correlate with CXCL10 in dsRNA-stimulated human fibroblasts and in at least one more species, using genes with a Spearman correlation value above 0.3 (see Fig. 3d and Supplementary Information).

*Analysis of different evolutionary modes: coding sequence evolution analysis.* The ratio dN/dS (non-synonymous to synonymous codon substitutions) of human genes across the mammalian clade was obtained from a previous study that used orthologous genes from 29 mammals<sup>72</sup>. Distributions of dN/dS values were computed for each of the three groups of genes with low, medium and high divergence in response to dsRNA, and are plotted in Fig. 4a.

*Rate of gene gain and loss analysis.* The significance at which a gene's family has experienced a higher rate of gene gain and loss in the course of vertebrate evolution, in comparison with other gene families, was retrieved from ENSEMBL<sup>73</sup>. The statistics provided by ENSEMBL are calculated using the CAFE method<sup>74</sup>, which estimates the global birth and death rate of gene families and identifies gene families that have accelerated rates of gain and loss. Distributions of the *P* values from this statistic were computed for each of the three groups of genes with low, medium and high divergence in response to dsRNA and are plotted as the negative logarithm values in Fig. 4b.

*Gene age analysis.* Gene age estimations were obtained from ProteinHistorian<sup>75</sup>. To ensure that the results were not biased by a particular method of ancestral protein family reconstruction or by specific gene family assignments, we used eleven different estimates for mammalian genes (combining five different databases of protein families with two different reconstruction algorithms for age estimation, as well as an estimate from the phylostratigraphic approach). For each gene, age was defined with respect to the species tree, where a gene's age corresponds to the branch in which its family is estimated to have appeared (thus, larger numbers indicate evolutionarily older genes).

Data for gene age in comparison with divergence in response to dsRNA are shown in Fig. 4c (using Panther7 phylogeny and Wagner reconstruction algorithm) and in Supplementary Fig. 17a (for all 11 combinations of gene family assignments and ancestral family reconstructions). See additional analyses in Supplementary Information.

*Cellular protein–protein interaction analysis.* Data on the number of experimentally validated PPIs for human genes were obtained from STRING (version 10)<sup>76</sup>. Distributions of

PPIs for genes with low, medium and high divergence in response to dsRNA are plotted in Fig. 4d.

*Host–virus interaction analysis.* Data on host–virus protein–protein interactions were downloaded from the VirusMentha database<sup>43</sup>, and combined with two additional studies that have annotated host–virus protein–protein interactions<sup>6,44</sup>. We split the 955 dsRNA-responsive genes into genes with known viral interactions (genes whose protein products were reported to interact with at least one viral protein), and genes with no known viral interactions: ‘viral interactors’ and ‘no viral interactions’, respectively, in Fig. 4e. In addition, we define a subset of genes within the viral interactors set: those known to interact with viral proteins that are immunomodulators (proteins known to target the host immune system and modulate its response<sup>45</sup>).

We note that the results presented in Fig. 4e are in agreement with previous analyses that are based on all human genes and on coding sequence evolution<sup>46</sup>. However, the overlap in the sets of genes between the previous analyses and the one presented here is small (for example, in one published study<sup>46</sup> there were 535 human genes with known interactions with pathogens, 57 of which overlap with the 955 genes that are the basis of the current analysis).

#### **Additional experiments with human fibroblasts and human skin tissue**

Additional experiments were performed with human dermal fibroblasts and with cells extracted from human skin tissues to study in greater detail the relationship between response divergence across species and cell–cell variability. See Supplementary Methods and Supplementary Discussion for details.

#### **Cross-species bone marrow-derived phagocyte stimulation with LPS and dsRNA**

*Tissue culture.* Primary bone marrow-derived mononuclear phagocytes originating from females of four different species (black 6 mouse, brown Norway rat, rabbit and pig) were obtained from PelloBiotech. Twenty-four hours before the start of the stimulation time course, cells were thawed and split into 12-well plates (500,000 cells per well). Cells were stimulated with: (1) 100 ng/ml LPS (Invivogen, tlr1-smlps), or with (2) 1 µg/ml high-molecular weight poly I:C (Invivogen, tlr1-pic) transfected with 2 µl/ml Lipofectamin 2,000 (ThermoFisher, 11668027). LPS stimulation time courses of 0, 2, 4, 6 h were performed for all species. Poly I:C stimulations were performed for rodents for 0, 2, 4, 6 h. We also processed cells for bulk RNA-seq for 0 and 4 h stimulation time points. Details on the individuals used in each technique are listed in Supplementary Table 2.

*Library preparation for single cells using microfluidic droplet cell capture.* Following stimulation, cells were collected using Cell Dissociation Solution Non-enzymatic (Sigma-Aldrich, C5914), washed and resuspended in  $1 \times$  PBS with 0.5% (w/v) BSA. Cells were then counted and loaded on the 10 $\times$  Chromium machine aiming for a targeted cell recovery of 5,000 cells according to the manual. Libraries were prepared following the Chromium Single Cell 3' v2 Reagent Kit Manual<sup>77</sup>. Libraries were sequenced on Illumina HiSeq 4000 instrument with 26 bp for read 1 and 98 bp for read 2.

*Library preparation and sequencing for bulk RNA-seq.* Total RNA was extracted and libraries were prepared as described in the fibroblasts section. Pooled samples were sequenced on an Illumina HiSeq 4000 instrument, using paired-end 75-bp reads.

*Quantifying gene expression in bulk RNA transcriptomics.* Adaptor sequences and low-quality score bases were trimmed using Trim Galore (version 0.4.1). Trimmed reads were mapped and gene expression was quantified using Salmon: (version 0.9.1)<sup>54</sup> with the following command: 'salmon quant -i [index\_file\_directory] / -l ISR -p 8--seqBias--gcBias--posBias -q -o [output\_directory] -l -g [ENSEMBL\_transcript\_to\_gene\_file]--useVBOpt--numBootstraps 100'. Mouse samples were mapped to mouse transcriptome (ENSEMBL, version 84). We note that we used the bulk data only for TSS analysis. For differential expression analysis, we used an in silico bulk from the single-cell data (see below).

*Quantifying gene expression in microfluidic droplet cell capture data.* Microfluidic droplet cell capture data was first quantified using 10 $\times$  Genomics' Cell Ranger Single-Cell Software Suite (version 2.0, 10 $\times$  Genomics Inc.)<sup>77</sup> against the relevant genome (ENSEMBL, version 84). We removed cells with fewer than 200 genes or more than 10% mitochondrial reads. To remove potential doublets, we excluded the top 10% of cells expressing the highest numbers of genes. Genes expressed in less than 0.5% of the cells were excluded from the calculations. We then filtered cells that expressed fewer than 10% of the total number of filtered genes.

Since bone marrow-derived phagocytes may include secondary cell populations, we focused our analysis on the major cell population. We identified clusters within each data set, using the Seurat<sup>78</sup> functions RunPCA, followed by FindClusters (using 20 dimensions from the PCA, default perplexity and a resolution of 0.1) and have taken the cells belonging to the largest cluster for further analysis, resulting in a less heterogeneous population of cells. A lower resolution of 0.03 was used for rabbit-LPS4, rabbit-LPS2, mouse-PIC2, mouse-PIC4; and 0.01 for rabbit-LPS6.

*Quantifying gene expression divergence in response to immune challenge.* We created an in silico bulk table by summing up the UMIs of the post-QC single cells belonging to the largest cluster of cells, in each of the samples. We then used the three replicates in unstimulated conditions and in 4 h LPS stimulation to perform a differential expression analysis using DESeq2<sup>79</sup> Wald test, and *P* values were adjusted for multiple testing by estimating the FDR. A similar procedure was performed with mouse and rat dsRNA stimulation (with 4 h dsRNA stimulation versus unstimulated conditions).

To quantify transcriptional divergence in immune response between species, we focused on genes that have annotated one-to-one orthologues across the studied species.

We define a measure of response divergence by calculating the differences between the fold-change estimates across the orthologues: response divergence =  $\log[1/3 \times \sum_j (\log[\text{FC}_{\text{pig}}] - \log[\text{FC}_{\text{glire}_j})^2]$ . For each gene, the fold-change in the outer group (pig), is subtracted from the fold-change in the orthologues of the three glires (mouse, rat and rabbit), and the average of the square values of these subtractions is taken as the response divergence measure. In most of the analyses, we focus on the 2,336 LPS-responsive genes—genes that are differentially expressed in response to LPS (genes that have an FDR-corrected *P* < 0.01 in mouse, and have annotated one-to-one orthologues in the other three species).

*Promoter elements, gene function and cell–cell variability analyses.* Promoter elements (TATA and CGIs), gene function and cell–cell variability analyses were performed as described in the fibroblasts section. Mouse genes were used as the reference for gene function and TSS annotations. For variability analysis, we used one representative replicate out of three.

### **Statistical analysis and reproducibility**

Statistical analyses were done with R version 3.3.2 for Fisher's exact test, two-sample Kolmogorov–Smirnov test and Mann–Whitney test. Data in boxplots represent the median, first quartile and third quartile with lines extending to the furthest value within 1.5 of the inter-quartile range (as implemented by the R function `geom_boxplot`). Violin plots show the kernel probability density of the data (as implemented by the R function `geom_violin`).

All cross-species bulk RNA-Seq replicates were successful, except for one macaque individual in which the treated sample had a low RNA quality and was removed from the analysis (along with the matching control). All cross-species ChIP–seq replicates were successful. Cross-species scRNA-seq of fibroblasts was performed in two biological

replicates. Results throughout the manuscript relate to the second cross-species biological replicate, for which a higher proportion of cells passed technical quality control. Three out of three replicates for each species and condition were successful when preparing single-cell libraries for mononuclear phagocytes, except for two libraries that failed at the emulsion preparation stage. Two out of two replicates of single-cell in situ RNA hybridization assay were performed and both are shown.

### Reporting summary

Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper.

### Code availability

Scripts for major analyses are available at [https://github.com/Teichlab/innate\\_evo](https://github.com/Teichlab/innate_evo).

### Data availability

Sequencing data have been deposited in ArrayExpress with the following accessions: [E-MTAB-5918](#), [E-MTAB-5919](#), [E-MTAB-5920](#), [E-MTAB-6754](#), [E-MTAB-6773](#), [E-MTAB-5988](#), [E-MTAB-5989](#), [E-MTAB-6831](#), [E-MTAB-6066](#), [E-MTAB-7032](#), [E-MTAB-7037](#), [E-MTAB-7051](#) and [E-MTAB-7052](#).

51. Kilpinen, H. *et al.* Common genetic variation drives molecular heterogeneity in human iPSCs. *Nature* **546**, 370–375 (2017).
52. Schmidl, C., Rendeiro, A. F., Sheffield, N. C. & Bock, C. CHIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors. *Nat. Methods* **12**, 963–965 (2015).
53. Picelli, S. *et al.* Full-length RNA-seq from single cells using Smart-seq2. *Nat. Protocols* **9**, 171–181 (2014).
54. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419 (2017).
55. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).
56. Nourmohammad, A. *et al.* Adaptive evolution of gene expression in *Drosophila*. *Cell Reports* **20**, 1385–1395 (2017).

57. Zhang, H. M. *et al.* AnimalTFDB: a comprehensive animal transcription factor database. *Nucleic Acids Res.* **40**, D144–D149 (2012).
58. Binns, D. *et al.* QuickGO: a web-based tool for Gene Ontology searching. *Bioinformatics* **25**, 3045–3046 (2009).
59. Kent, W. J. *et al.* The human genome browser at UCSC. *Genome Res.* **12**, 996–1006 (2002).
60. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359 (2012).
61. Li, H. *et al.* The sequence alignment/map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
62. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137 (2008).
63. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).
64. Kuhn, R. M. *et al.* The UCSC genome browser database: update 2007. *Nucleic Acids Res.* **35**, D668–D673 (2007).
65. Mathelier, A. *et al.* JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. *Nucleic Acids Res.* **44**, D110–D115 (2016).
66. Grant, C. E., Bailey, T. L. & Noble, W. S. FIMO: scanning for occurrences of a given motif. *Bioinformatics* **27**, 1017–1018 (2011).
67. Pollard, K. S., Hubisz, M. J., Rosenbloom, K. R. & Siepel, A. Detection of nonneutral substitution rates on mammalian phylogenies. *Genome Res.* **20**, 110–121 (2010).
68. Kolodziejczyk, A. A. *et al.* Single cell RNA-sequencing of pluripotent states unlocks modular transcriptional variation. *Cell Stem Cell* **17**, 471–485 (2015).
69. Vallejos, C. A., Marioni, J. C. & Richardson, S. BASiCS: Bayesian analysis of single-cell sequencing data. *PLOS Comput. Biol.* **11**, e1004333 (2015).
70. Martinez-Jimenez, C. P. *et al.* Aging increases cell-to-cell transcriptional variability upon immune stimulation. *Science* **355**, 1433–1436 (2017).

71. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L. & Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. *Bioinformatics* **27**, 431–432 (2011).
72. Lindblad-Toh, K. *et al.* A high-resolution map of human evolutionary constraint using 29 mammals. *Nature* **478**, 476–482 (2011).
73. Herrero, J. *et al.* Ensembl comparative genomics resources. *Database* **2016**, bav096 (2016).
74. De Bie, T., Cristianini, N., Demuth, J. P. & Hahn, M. W. CAFE: a computational tool for the study of gene family evolution. *Bioinformatics* **22**, 1269–1271 (2006).
75. Capra, J. A., Williams, A. G. & Pollard, K. S. ProteinHistorian: tools for the comparative analysis of eukaryote protein origin. *PLOS Comput. Biol.* **8**, e1002567 (2012).
76. Szklarczyk, D. *et al.* STRING v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res.* **43**, D447–D452 (2015).
77. Zheng, G. X. *et al.* Massively parallel digital transcriptional profiling of single cells. *Nat. Commun.* **8**, 14049 (2017).
78. Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. *Nat. Biotechnol.* **33**, 495–502 (2015).
79. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold-change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).

[Author: Please ensure that the following information is included in the figure legends where relevant. Sample size (exact  $n$  number); a statement of replicability (how many times was experiment replicated in the laboratory); description of sample collection (clarify whether technical or biological replicates and include how many animals, litters, cultures, etc.); state the statistical test used and give  $P$  values; define centre values (median or average) and error bars. For figures/images that are reproduced or adapted from a third party, it is important that you confirm that permission has been obtained and that appropriate acknowledgement of the copyright holder is given.]

**Extended Data Fig. 1 | Fibroblast response to dsRNA and IFN $\beta$  across species.** To study the similarity in response to treatment across species, we plotted the fold-change values of all

expressed genes (with one-to-one orthologues) between pairs of species (human–macaque, mouse–rat and human–mouse) in response to dsRNA (poly I:C) (**a–c**). As a control, we performed the same procedure with IFNB stimulations (**d–f**). Fold-changes were inferred from differential expression analyses, determined by the exact test in the edgeR package<sup>6</sup> and based on  $n = 6, 5, 3$  and  $3$  individuals from human, macaque, rat and mouse, respectively. Spearman correlations between all expressed one-to-one orthologues are shown in grey, Spearman correlations between the subset of differentially expressed genes (FDR-corrected  $P < 0.01$  in at least one species) appear in black. Number of genes shown is  $n = 11,035, 11,005, 11,137, 10,851, 10,826$  and  $10,957$  in **a–f**, respectively. Genes are coloured blue if they were differentially expressed (FDR-corrected  $P < 0.01$ ) in both species, purple if they were differentially expressed in only one species, or red if they were not differentially expressed. **g, h**, Density plots of ratio of fold-change in response to dsRNA or to IFNB. **g**, Comparison between human and macaque orthologues in dsRNA response. **h**, Comparison between human and mouse orthologues in IFNB response. **i**, Dendrogram based on the fold-change in response to dsRNA or to IFNB across 9,835 one-to-one orthologues in human, macaque, rat and mouse.

**Extended Data Fig. 2 | Correspondence of transcriptional divergence and divergence of active promoters and enhancers.** Comparison of divergence in transcriptional response to dsRNA with divergence of active chromatin marks in active promoters (**a**, profiled using H3K4me3 in proximity to gene’s TSS) and enhancers (**b**, H3K27ac without overlapping H3K4me3). Chromatin marks were linked to genes on the basis of their proximity to the gene’s TSS. Chromatin marks were obtained from  $n = 3$  individuals in each of the four species, from fibroblasts stimulated with dsRNA or left untreated. The statistics are based on  $n = 855, 818$  and  $813$  human genes that have a linked H3K4me3 mark with a syntenic region in macaque, rat and mouse, respectively (**a**); and on  $n = 326, 241$  and  $242$  human genes that have a linked H3K27ac mark with a syntenic region in macaque, rat and mouse, respectively (**b**). Each panel shows the fraction of conserved marks between human and macaque, rat or mouse, in genes that have high, medium and low divergence in their transcriptional response. In each column, the histone mark’s signal was compared between human and the syntenic region in one of the three other species. If an active mark was found in the corresponding syntenic region, the linked gene was considered to have a conserved active mark (promoter or enhancer). The fractions of genes with conserved promoters (or enhancers) in each pair of species were compared between high- and low-divergence genes using a one-sided Fisher’s

exact test. When comparing active promoter regions of high- versus low-divergence genes, we observe that low-divergence genes have a significantly higher fraction of conserved marks in rodents. This suggests an agreement between divergence at the transcriptional and chromatin levels in active promoter regions. In active enhancer regions, we do not observe these patterns, suggesting that the major contribution to divergence comes from promoters.

**Extended Data Fig. 3 | Comparison of response divergence of genes containing various promoter elements.** Comparison of response divergence between genes with and without a TATA-box and CGI. Left, fibroblasts ( $n = 14, 14, 633$  and  $294$  differentially expressed genes with only TATA-box element, with both CGI and TATA-box elements, with only CGI, and with neither element in their promoters, respectively); right, phagocytes ( $n = 13, 29, 1,718$  and  $576$  differentially expressed genes with only a TATA-box element, with both CGI and TATA-box elements, with only a CGI, and with neither element in their promoters, respectively). Genes with a TATA-box without a CGI have higher response divergence than genes with both elements. Genes with a CGI but without a TATA-box diverge more slowly than genes with both elements. Genes with both elements do not differ significantly in their divergence from genes lacking both elements (one-sided Mann–Whitney test). Data in boxplots represent the median, first quartile and third quartile with lines extending to the furthest value within 1.5 of the IQR.

**Extended Data Fig. 4 | Response divergence of molecular processes upregulated in immune response.** Left, distributions of divergence values of  $n = 955$  dsRNA-responsive genes in fibroblasts and subsets of this group belonging to different biological processes. For each functional subset, the distribution of divergence values is compared with the set of 955 dsRNA-responsive genes using a one-sided Mann–Whitney test. FDR-corrected  $P$  values are shown above each group and group size is shown inside each box. Right, distributions of divergence values of  $n = 2,336$  LPS-responsive genes in mononuclear phagocytes and subsets of this group belonging to different biological processes. For each functional subset, the distribution of divergence values is compared with the set of 2,336 LPS-responsive genes. FDR-corrected  $P$  values (one-sided Mann–Whitney test) are shown above each group and group size is shown inside each box. Data in boxplots represent the median, first quartile and third quartile with lines extending to the furthest value within 1.5 of the IQR. **[Author: ED Figure is not labelled a and b so I have changed the legend to left and right, ok?]**

**Extended Data Fig. 5 | Cell–cell variability versus response divergence across species and conditions in fibroblasts after dsRNA stimulation.** Cell–cell variability values, as

measured with DM across individual cells, compared with response divergence between species (grouped into low, medium and high divergence). Variability values are based on  $n = 29, 56, 55, 35$  human cells,  $n = 20, 32, 29, 13$  rhesus cells,  $n = 33, 70, 65, 40$  rat cells, and  $n = 53, 81, 59, 30$  mouse cells, stimulated with dsRNA for 0, 2, 4 and 8 h, respectively. Rows represent different dsRNA stimulation time points (0, 2, 4 and 8 h), and columns represent different species as shown. High-divergence genes were compared with low-divergence genes using a one-sided Mann–Whitney test. Data in boxplots represent the median, first quartile and third quartile with lines extending to the furthest value within 1.5 of the IQR.

**Extended Data Fig. 6 | Cell–cell variability versus response divergence across species and conditions in mononuclear phagocytes after LPS stimulation.**

Cell–cell variability values, as measured with DM across cells, compared with response divergence between species (grouped into low, medium and high divergence). Variability values are based on  $n = 3,519, 4,321, 3,293, 2,126$  mouse cells,  $n = 2,266, 2,839, 1,963, 1,607$  rat cells,  $n = 3,275, 1,820, 1,522, 1,660$  rabbit cells, and  $n = 1,748, 1,614, 1,899, 1,381$  pig cells, stimulated with LPS for 0, 2, 4 and 6 h, respectively. Rows represent different LPS stimulation time points (0, 2, 4 and 6 h), and columns represent different species as shown. High-divergence genes were compared with low-divergence genes using a one-sided Mann–Whitney test. Data in boxplots represent the median, first quartile and third quartile with lines extending to the furthest value within 1.5 of the IQR.

**Extended Data Fig. 7 | Cell–cell variability of cytokine expression in single cell in situ RNA hybridization assay combined with flow cytometry (PrimeFlow).**

PrimeFlow measurement of two cytokine genes (*IFNB* and *CXCL10*) that show high cell–cell variability in scRNA-seq. As controls, two genes matched on expression levels (*ATXN2L* and *ADAM32*) but that show low cell–cell variability in scRNA-seq data are shown. As the expression of cytokines is at the low end of the distribution, we also chose two genes with middle-range expression values (*ADAMTSL3* and *BRD2*) as additional controls. The experiment was performed in  $n = 2$  independent replicates, originating from the same individual. Both replicates are shown. **a**, Pseudocolour contour plot for RNA target expression in dsRNA-stimulated human fibroblasts. The  $x$ -axis shows area of side scatter (SSC-A) and the  $y$ -axis shows fluorescent signal for target RNA probes. RNA targets detected by the same fluorescent channel are displayed together. Top, *IFNB* and control genes *BRD2* and *ATXN2L*, type 1 probe, Alexa Fluor™ 647. Bottom, *CXCL10* and control genes *ADAMTSL3* and *ADAM32*, type 10 probe, Alexa Fluor™ 568. The cytokine genes display a broader range of

fluorescence signal than the controls. **b**, Histograms comparing fluorescence of cytokine and control pairs (*IFNB*–*BRD2* for type 1 probe and *CXCL10*–*ADAM32* for type 10 probe). The histograms show a bimodal distribution of expression signal for the two cytokine genes (*IFNB* and *CXCL10*, red), but not for controls (blue). This agrees with scRNA-seq data in which *CXCL10* and *IFNB* display high levels of cell-to-cell variability.

**Extended Data Fig. 8 | Cell–cell variability levels and response divergence of cytokines, transcription factors and kinases in response to LPS stimulation of phagocytes.** A scatter plot showing divergence in response to LPS across species and transcriptional cell–cell variability in mouse mononuclear phagocytes following 4 h of LPS treatment, in  $n = 2,262$  LPS-responsive genes. Purple, cytokines; green, transcription factors; beige, kinases. The distributions of divergence values and cell–cell variability values of each of the three functional groups are shown above and to the right of the scatter plot, respectively.

**Extended Data Fig. 9 | Cell–cell variability levels in cytokines, transcription factors and kinases across species and stimulation time points.** Violin plots showing the distribution of cell–cell variability values (DM) of cytokines, transcription factors and kinases during immune stimulation. Left, fibroblast dsRNA stimulation time course. Number of cells used in each species (at 2, 4, 8 h dsRNA, respectively): human, 56, 55, 35; macaque, 32, 29, 13; rat, 70, 65, 40; mouse, 81, 59, 30. Right, phagocyte LPS stimulation time course. Number of cells used in each species (at 2, 4, 6 h LPS, respectively): mouse, 4,321, 3,293, 2,126; rat, 2,839, 1,963, 1,607; rabbit, 1,820, 1,522, 1,660; pig, 1,614, 1,899, 1,381. For both panels, colours as in Fig. 3c. Comparisons between groups of genes were performed using one-sided Mann–Whitney tests. Violin plots show the kernel probability density of the data.

**Extended Data Fig. 10 | Percentage of cells expressing cytokines, transcription factors and kinases.** Histograms showing the percentage of fibroblasts expressing cytokines (top), transcription factors (middle) and kinases (bottom) following 4 h dsRNA stimulation, in human, macaque, rat and mouse cells (based on  $n = 55, 29, 65$  and  $59$  cells, respectively). The percentage of expressing cells is divided into 13 bins ( $x$ -axis). The  $y$ -axis represents the fraction of genes from this gene class (for example, cytokines) that are expressed in each bin (for example, in human, nearly 30% of the cytokine genes ( $y$ -axis) are expressed in the first bin, corresponding to expression in fewer than 8% of cells).